Just so good to see PMR on the plenary stage at #ACR22, after #EULAR2022 too SAPHYR study: sarilumab allows for - a quicker steroid wean & less toxicity - but also far more disease remission, quicker symptom resolution, better quality of life Game-changing. ABST1676 @RheumNow https://t.co/ZVqlMNoniu https://t.co/Fv3VRZrKGe

• https://twitter.com/drdavidliew/status/1533040378386993153

Do you think you need a #steroid sparing Rx in #polymyalgia #rheumatica? +data in #sarilumab w 14 wk ped taper. No diverticulitis, ?Stacking comparator grp to flare as past steroid tapering caused a flare. But that is an unmet need after long pred Rx Abst#1543 #ACR22 @RheumNow https://t.co/Q1bhYs7LEz

Intersting discussion post Plenary this AM - Agree w/RS that we should taper steroid - Is there a disease modifying benefit? I think not - When should this be used? Disagree w/RS, I would not use unless relapsing/refractory and requiring >10mg pred #ACR22 @RheumNow https://t.co/ylGXk2sca7

• https://twitter.com/EBRheum/status/1591864082705129472

Are your SpA pts planning on conceiving? Be careful with NSAID use French study found age and NSAID use associated with longer time-to-conception. Factors not associated: smoking, BASDAI score, DMARD use #ACRBest Abs#1673 @RheumNow #ACR22 https://t.co/D63XTY7IB8

Ab1674 #ACR22 HCQ in pregnancy is SAFE and Standard of Care! In Utero Exposure to HCQ does NOT ass w/ ocular toxicity: OCTs 5 yrs after birth 👀 PATCH study of HCQ to reduce CHB in pregnancy 18% CHB (historical) -> 7% treated risk OCT: retinal thickness nml at 5 yrs @RheumNow

Are TNFi or IL-6Ri safe in rheumatic irAEs from ICI Rx? Multiple big US centers retrospective: TNFi, IL-6Ri vs MTX p>0.05, but may be approx 2x risk of cancer progression Has made me more cautious about TNFi, IL-6Ri - use MTX when you can Lovely work! ABST1669 #ACR22 @RheumNow https://t.co/cfAT1pQZ7I

Maya Buch on major adverse CV events in tofa vs TNFi. Post-hoc analysis of phase 3b/4 data looking at cohort enriched for CV events. @RheumNow #ACR22 #LateBreaking

L06 #ACR22 ORAL Surveillance Updates! Composite of all ischemic CV events and HF did NOT show difference b/w TOFA vs TNFi But, MACE numerically higher with Tofa w/ h/o ASCVD Highest CV risk in TOFA 10 mg BID, 2/2 VTE risk Most important risk is pt's individual risks @RheumNow https://t.co/jPPX7f5GRE